ClinicalTrials.gg
CompletedNCT06055985ATLANTISUpdated Apr 6, 2026

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

A Phase 2 interventional study of Placebo and UCB0022 in Parkinson Disease, sponsored by UCB Biopharma SRL. Completed at 61 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2025, 1 year 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Parkinson Disease by UCB S.A. — none open to participants now, none under way, none of them phase 3. Parkinson Disease · UCB S.A..

Enrollment
14th of 34
207 · median 123
Started
2023
the only one that year
Phase 2
5 of 44
none open now
Registered
44th of 44
by date

Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 2, and was the 44th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 44 studies in Parkinson Disease by UCB S.A. is open now. The open studies under Parkinson Disease, anywhere →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies in Parkinson Disease by UCB S.A. as a file.
02

Study summary

The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • Phase 2
  • UCB0022
  • wearing-off
  • motor fluctuations
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participant must be 35 to 85 years of age (inclusive) at the time of signing the form (ICF)
  • Study participant is diagnosed with Parkinson's disease (PD) (based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic criteria performed at the Screening Visit) and diagnosed ≥5 years before the Screening Visit (based on historical medical- information documented by the investigator)
  • Study participant has significant daily motor fluctuations
  • Study participant is able to complete a Hauser PD symptoms diary and differentiate between the ON and OFF states
  • Study participant is responsive to levodopa and currently receiving treatment with oral daily doses of levodopa combination (levodopa/carbidopa or levodopa/benserazide) with or without oral adjunctive antiparkinsonian therapies (based on historical clinical data)
  • Study participant has disease severity Stages I-III (modified Hoehn and Yahr staging) during ON state
  • Study participant agrees to not post personal medical data or information related to the study on social media until study completion
  • Study participant has body weight ≥45 kg and within 18 to 30 kg/m\^2 (inclusive)
  • Study participant may be male or female:

    1. A male study participant must agree to use during the Treatment Period and for at least 2 weeks after the last dose of study treatment and refrain from donating sperm during this period
    2. A female study participant must not be a woman of (WOCBP)

Exclusion criteria

Exclusion Criteria:

  • Study participant is diagnosed with any form of Parkinsonism other than idiopathic PD (eg, atypical or secondary Parkinsonism)
  • Study participant is diagnosed with dementia or has important cognitive dysfunction, as determined by (MoCA) \<23 at screening
  • Study participant has a history of neurosurgical intervention for PD (including DBS, thalamotomy, and experimental cell therapy or gene therapy)
  • Participant has a severe peak dose or biphasic dyskinesia at screening, defined by Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) items 4.2 score 4 or as per investigator opinion
  • Participant has a history of major depression or psychotic disorder or any other psychiatric condition within the past 5 years, that, as per investigator opinion, could jeopardize or would compromise the study participant's ability to participate in the study
  • Study participant has a history of narrow angle glaucoma
  • Study participant has a history of melanoma
  • Study participant has current untreated hypertension
  • Study participant has a history of hypertensive crisis and/or hypertensive encephalopathy, unless the underlying cause was unequivocally identified and has been removed
  • Study participant has orthostatic hypotension requiring medication or a current history of "" orthostatic hypotension as per the investigator's opinion (eg, recurrent orthostatic presyncope or syncope)
  • Study participant has a history over the past 12 months or between the Screening and Baseline Visits of any clinically significant arrythmia, myocardial infarction, stroke, , moderate or severe congestive heart failure (either Class III or IV or known \<40%)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    UCB0022-Dose A

    Study participants randomized to this arm will receive UCB0022 Dose A orally administered as tablet during the Treatment Period.

    Drug: UCB0022

  • Experimental
    UCB0022-Dose B

    Study participants randomized to this arm will receive UCB0022 Dose B orally administered as tablet during the Treatment Period.

    Drug: UCB0022

  • Placebo comparator
    Placebo

    Study participants randomized to this arm will receive matching placebo orally administered as tablet during the Treatment Period.

    Other: Placebo

Interventions

  • OtherPlacebo

    Study participants will receive placebo orally administered as tablet at pre-specified time points during the study.

  • Study participants will receive UCB0022 dose A or B orally administered as tablet at pre-specified time points during the Treatment Period.

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Visit 9 (Day 70) in the average number of hours/day of OFF time, as assessed by the study participant-completed Hauser PD symptoms diary over 3 consecutive days

    The Hauser Parkinson's disease (PD) symptoms diary is a study participant-completed diary that records the daily ON time and OFF time of study participants with PD with motor fluctuations and dyskinesia.

    Time frame: From Baseline (Day 1) to Visit 9 (Day 70)

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 2 weeks after the final dose.

    Time frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)

  2. Incidence of treatment-emergent serious adverse events (SAEs)

    A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent disability/incapacity * Is a congenital anomaly/birth defect * Important medical events Treatment-emergent AEs are defined as those AEs that have a start date on or following the first dose of investigational medicinal product (IMP).

    Time frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)

  3. Incidence of TEAEs leading to withdrawal from the study

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs starting after the time of first IMP administration up to and including 2 weeks after the final dose.

    Time frame: From Baseline (Day 1) to End of Safety Follow-up (up to Week 12)

  4. Average Ctrough of UCB0022 and its active N-desmethyl-UCB0022 metabolite at Visit 9 (Day 70)

    Ctrough: The predose observed plasma concentration (average, per visit) will be plotted and depicted graphically to assess trajectory to steady-state for parent and active metabolites.

    Time frame: at Visit 9 (Day 70)

07

Study locations

61 sites
  • Pd0060 50506
    Phoenix, Arizona 85004, United States
  • Pd0060 50590
    Scottsdale, Arizona 85258, United States
  • Pd0060 50608
    Little Rock, Arkansas 72205, United States
  • Pd0060 50519
    Fountain Valley, California 92708, United States
  • Pd0060 50428
    Fresno, California 93710, United States
  • Pd0060 50601
    Loma Linda, California 92354, United States
  • Pd0060 50589
    Los Alamitos, California 90720, United States
  • Pd0060 50587
    Los Angeles, California 90033, United States
  • Pd0060 50452
    Pasadena, California 91106, United States
  • Pd0060 50598
    Englewood, Colorado 80113, United States
  • Pd0060 50628
    New Haven, Connecticut 06519, United States
  • Pd0060 50610
    Newark, Delaware 19713, United States
  • Pd0060 50600
    Altamonte Springs, Florida 32714, United States
  • Pd0060 50616
    Aventura, Florida 33180, United States
  • Pd0060 50596
    Boca Raton, Florida 33486, United States
  • Pd0060 50524
    Bradenton, Florida 34205, United States
  • Pd0060 50647
    DeLand, Florida 32720, United States
  • Pd0060 50577
    Doral, Florida 33172, United States
  • Pd0060 50584
    Hollywood, Florida 33021, United States
  • Pd0060 50582
    Miami, Florida 33122, United States
  • Pd0060 50579
    Miami, Florida 33125, United States
  • Pd0060 50449
    Miami, Florida 33133, United States
  • Pd0060 50580
    Miami, Florida 33176, United States
  • Pd0060 50597
    Naples, Florida 34105, United States
  • Pd0060 50591
    Ocala, Florida 34470, United States
  • Pd0060 50605
    Port Orange, Florida 32127, United States
  • Pd0060 50620
    St. Petersburg, Florida 33710, United States
  • Pd0060 50603
    Tampa, Florida 33609, United States
  • Pd0060 50585
    Winter Park, Florida 32789, United States
  • Pd0060 50075
    Augusta, Georgia 30912, United States
  • Pd0060 50595
    Indianapolis, Indiana 46256, United States
  • Pd0060 50319
    Iowa City, Iowa 52242, United States
  • Pd0060 50074
    Kansas City, Kansas 66160, United States
  • Pd0060 50561
    Lexington, Kentucky 40536-0284, United States
  • Pd0060 50615
    Boston, Massachusetts 02118, United States
  • Pd0060 50085
    Boston, Massachusetts 02215, United States
  • Pd0060 50627
    North Dartmouth, Massachusetts 02747, United States
  • Pd0060 50110
    Ann Arbor, Michigan 48109-0944, United States
  • Pd0060 50545
    East Lansing, Michigan 48824, United States
  • Pd0060 50386
    Farmington Hills, Michigan 48334, United States
  • Pd0060 50613
    Grand Rapids, Michigan 49503, United States
  • Pd0060 50614
    New York, New York 10021, United States
  • Pd0060 50521
    New York, New York 10029, United States
  • Pd0060 50612
    Raleigh, North Carolina 27607, United States
  • Pd0060 50087
    Centerville, Ohio 45459, United States
  • Pd0060 50622
    Cleveland, Ohio 44195, United States
  • Pd0060 50076
    Columbus, Ohio 43221, United States
  • Pd0060 50604
    Dayton, Ohio 45449, United States
  • Pd0060 50527
    Toledo, Ohio 43614, United States
  • Pd0060 50398
    Tulsa, Oklahoma 74136, United States
  • Pd0060 50607
    Portland, Oregon 97210, United States
  • Pd0060 50619
    Rock Hill, South Carolina 29732, United States
  • Pd0060 50496
    Round Rock, Texas 78681, United States
  • Pd0060 50568
    San Antonio, Texas 78229, United States
  • Pd0060 50537
    Salt Lake City, Utah 84108, United States
  • Pd0060 50143
    Henrico, Virginia 23233, United States
  • Pd0060 50534
    Virginia Beach, Virginia 23456, United States
  • Pd0060 50440
    Bellevue, Washington 98004, United States
  • Pd0060 50292
    Kirkland, Washington 98034, United States
  • Pd0060 50419
    Spokane, Washington 99202, United States
  • Pd0060 50402
    Crab Orchard, West Virginia 25827, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2025, 16 months.

Of 96 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's 16 months is below that.

Counting every sponsor, half of 201 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2023
First posted
Sep 28, 2023
StartActual
Nov 17, 2023
Primary completionActual
Mar 31, 2025
CompletionActual
Apr 11, 2025
Results delay requested
Mar 30, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06055985
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Nov 17, 2023
Primary completion
Mar 31, 2025
Completion
Apr 11, 2025
Last update
Apr 6, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glovadalen

Start the discussion